2da busqueda

8/21/2019 2da Busqueda

1/16

Busqueda; buscadores web (27-01-2014)

1 alta vista; sin resultados ya que el computador me deriba a yahoo.es.

2Ask;

- http://www.ask.com/web?q=cpap+boussignac&search=&qsrc=0&o=0&l=dir&ad=dirN

1- Active humidification with Boussignac CPAP: in vitro studyof a new method.

Alonso-Iigo JM,Almela A,Albert A,Carratal JM,Fas MJ.Author information

AbstractOBJECTIVE:To carry out an in vitro study of Boussignac CPAP valve performance with a new humidificationmethod, using a heated humidifier.

METHODS:Two heated humidifiers were evaluated: Fisher & Paykel MR850, and Covidien Kendall Aerodyne2000. Baseline measurements were taken in all experimental conditions without humidification. TheBoussignac valve was adapted to the input of the humidification chamber. The system wasconnected to a test lung to assess the degree of pressurization. Hygrometric and pressuremeasurements were performed with the following gas flows: 10, 20, 30 and 40 L/min.

RESULTS:The mean values of pressure generated by the Boussignac valve were 1.99 0.02, 6.97 0.05,16.61 0.08 and 21.24 0.08 cm H2O, 10, 20, 30 and 40 L/min, respectively, no differences beingdetected between study groups. Overall absolute humidity was significantly greater with a heatedhumidifier than without humidification (range 40.01 0.57-25.46 0.49 compared to 0.16 0.13mgH2O/L, P < .001). Absolute humidity was significantly higher in Kendall Aerodyne 2000compared to MR850, regardless of the selected temperature and flow (P < .001).

CONCLUSIONS:This new method of Boussignac CPAP humidification yielded humidity values above 25 mg H2O/Lregardless of the heated humidifier and flow used. Pressurization values remained constant in eachexperimental situation and were not influenced by adding humidification. These data open up thepossibility of using Boussignac CPAP on different types of patients, with different interfaces and forlong periods of time.

KEYWORDS:

Boussignac, CPAP, active humidification, acute respiratory failure, noninvasive ventilation

2-Boussignac continuous positive airway pressure device inthe emergency care of acute cardiogenic pulmonary oedema:a randomized pilot study.Moritz F,Benichou J,Vanheste M,Richard JC,Line S,Hellot MF,Bonmarchand G,MullerJM.
http://www.ncbi.nlm.nih.gov/pubmed?term=Alonso-I%C3%B1igo%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=22906896http://www.ncbi.nlm.nih.gov/pubmed?term=Alonso-I%C3%B1igo%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=22906896http://www.ncbi.nlm.nih.gov/pubmed?term=Almela%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22906896http://www.ncbi.nlm.nih.gov/pubmed?term=Almela%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22906896http://www.ncbi.nlm.nih.gov/pubmed?term=Almela%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22906896http://www.ncbi.nlm.nih.gov/pubmed?term=Albert%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22906896http://www.ncbi.nlm.nih.gov/pubmed?term=Albert%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22906896http://www.ncbi.nlm.nih.gov/pubmed?term=Albert%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22906896http://www.ncbi.nlm.nih.gov/pubmed?term=Carratal%C3%A1%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=22906896http://www.ncbi.nlm.nih.gov/pubmed?term=Carratal%C3%A1%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=22906896http://www.ncbi.nlm.nih.gov/pubmed?term=Carratal%C3%A1%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=22906896http://www.ncbi.nlm.nih.gov/pubmed?term=Fas%20MJ%5BAuthor%5D&cauthor=true&cauthor_uid=22906896http://www.ncbi.nlm.nih.gov/pubmed?term=Fas%20MJ%5BAuthor%5D&cauthor=true&cauthor_uid=22906896http://www.ncbi.nlm.nih.gov/pubmed?term=Fas%20MJ%5BAuthor%5D&cauthor=true&cauthor_uid=22906896http://www.ncbi.nlm.nih.gov/pubmed/22906896http://www.ncbi.nlm.nih.gov/pubmed/22906896http://www.ncbi.nlm.nih.gov/pubmed?term=Moritz%20F%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Moritz%20F%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Benichou%20J%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Benichou%20J%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Benichou%20J%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Vanheste%20M%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Vanheste%20M%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Vanheste%20M%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Richard%20JC%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Richard%20JC%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Richard%20JC%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Line%20S%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Line%20S%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Line%20S%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Hellot%20MF%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Hellot%20MF%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Hellot%20MF%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Bonmarchand%20G%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Bonmarchand%20G%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Bonmarchand%20G%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Muller%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Muller%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Muller%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Muller%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Muller%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Muller%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Bonmarchand%20G%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Hellot%20MF%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Line%20S%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Richard%20JC%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Vanheste%20M%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Benichou%20J%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Moritz%20F%5BAuthor%5D&cauthor=true&cauthor_uid=12972896http://www.ncbi.nlm.nih.gov/pubmed/22906896http://www.ncbi.nlm.nih.gov/pubmed?term=Fas%20MJ%5BAuthor%5D&cauthor=true&cauthor_uid=22906896http://www.ncbi.nlm.nih.gov/pubmed?term=Carratal%C3%A1%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=22906896http://www.ncbi.nlm.nih.gov/pubmed?term=Albert%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22906896http://www.ncbi.nlm.nih.gov/pubmed?term=Almela%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22906896http://www.ncbi.nlm.nih.gov/pubmed?term=Alonso-I%C3%B1igo%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=22906896


2/16

Author information

AbstractThis study aimed to assess the short-term respiratory effects of a new portable device that deliversa continuous positive airway pressure via a face mask (Boussignac-CPAP) in patients with severeacute cardiogenic pulmonary oedema, and the feasibility of using this technique in an emergency

department. We prospectively studied 30 consecutive patients with acute cardiogenic pulmonaryoedema. They were randomly assigned either to the Boussignac-CPAP valve, which deliveredoxygen, or to standard oxygen delivery for a duration of 30 min. The end-expiratory pressurereached 9.3+/-0.3 cm H2O with the Boussignac-CPAP valve. At the end of the 30 min period, thedecreases in respiratory rate and muscular activity were significantly greater among patientsassigned to the Boussignac-CPAP valve compared with those on standard oxygen delivery [24+/-1.6 breaths/min, median 24 (15-37) versus 28.5+/-1.9, median 27 (16-38) and 1.3+/-0.2, median 1(0-4) versus 2.7+/-0.3, median 2 (0-4), respectively]. Moreover, the arterial oxygen tension toinspired oxygen concentration ratio and tidal volume were improved at the end of the 30 minBoussignac-CPAP period compared with baseline. Boussignac-CPAP was easily implemented andno side-effects were reported. Continuous positive pressure delivered using the Boussignac-CPAPdevice is feasible in an emergency care setting. It can quickly improve respiratory distress in acutecardiogenic pulmonary oedema patients. A larger trial should be initiated in such an emergencycare setting to demonstrate the effectiveness of the Boussignac-CPAP device.

3-[Laboratory testing measurement of FIO2 delivered byBoussignac CPAP system with an input of 100% oxygen].[Article in French]Templier F,Dolveck F,Baer M,Chauvin M,Fletcher D.Author information

Abstract

INTRODUCTION:CPAP (Continuous Positive Airway Pressure) is one of the treatments of the cardiogenic acutepulmonary edema (cAPE). Among the out-of-hospital used devices, Boussignac CPAP (Vygon)shows a good technical usability, but no analysis of delivered FIO2 is available.

OBJECTIVE:To measure the FIO2 delivered to patient, using Boussignac CPAP with an input of 100 vol %oxygen. Type of study. - Measurement in a laboratory testing.

MATERIAL AND METHOD:Measurement of delivered FIO2 in a three parameters environment: expiratory positive airwaypressure (EPAP), respiratory rate (RR) and required oxygen flow (ROF). Laboratory test: 100 vol %

oxygen input, with a ball-type flow regulator for oxygen 0-30 l x min(-1) (Mediline), BoussignacCPAP valve with manometer (Vygon), Michigan test lung, ventilator Csar (Taema), oxygenanalysis (Servomex) with paramagnetic sensor, with a response time < 10 s, pneumotachographe(Fleisch v 2).

RESULTS:Under 10 cmH2O EPAP, the required oxygen flow is < or = 30 l x min(-1). Measured FIO2 rangesfrom 70 to 100 vol %, for a volume per minute < or = 15 l x min(-1) except for a EPAP at 2.5 cmH2Owith a rate = 10 c min(-1) and a tidal volume (VT) at 1500 ml where the measured FIO2 is 60 vol %.
http://www.ncbi.nlm.nih.gov/pubmed/12972896http://www.ncbi.nlm.nih.gov/pubmed/12972896http://www.ncbi.nlm.nih.gov/pubmed?term=Templier%20F%5BAuthor%5D&cauthor=true&cauthor_uid=12706763http://www.ncbi.nlm.nih.gov/pubmed?term=Templier%20F%5BAuthor%5D&cauthor=true&cauthor_uid=12706763http://www.ncbi.nlm.nih.gov/pubmed?term=Dolveck%20F%5BAuthor%5D&cauthor=true&cauthor_uid=12706763http://www.ncbi.nlm.nih.gov/pubmed?term=Dolveck%20F%5BAuthor%5D&cauthor=true&cauthor_uid=12706763http://www.ncbi.nlm.nih.gov/pubmed?term=Dolveck%20F%5BAuthor%5D&cauthor=true&cauthor_uid=12706763http://www.ncbi.nlm.nih.gov/pubmed?term=Baer%20M%5BAuthor%5D&cauthor=true&cauthor_uid=12706763http://www.ncbi.nlm.nih.gov/pubmed?term=Baer%20M%5BAuthor%5D&cauthor=true&cauthor_uid=12706763http://www.ncbi.nlm.nih.gov/pubmed?term=Baer%20M%5BAuthor%5D&cauthor=true&cauthor_uid=12706763http://www.ncbi.nlm.nih.gov/pubmed?term=Chauvin%20M%5BAuthor%5D&cauthor=true&cauthor_uid=12706763http://www.ncbi.nlm.nih.gov/pubmed?term=Chauvin%20M%5BAuthor%5D&cauthor=true&cauthor_uid=12706763http://www.ncbi.nlm.nih.gov/pubmed?term=Chauvin%20M%5BAuthor%5D&cauthor=true&cauthor_uid=12706763http://www.ncbi.nlm.nih.gov/pubmed?term=Fletcher%20D%5BAuthor%5D&cauthor=true&cauthor_uid=12706763http://www.ncbi.nlm.nih.gov/pubmed?term=Fletcher%20D%5BAuthor%5D&cauthor=true&cauthor_uid=12706763http://www.ncbi.nlm.nih.gov/pubmed?term=Fletcher%20D%5BAuthor%5D&cauthor=true&cauthor_uid=12706763http://www.ncbi.nlm.nih.gov/pubmed/12706763http://www.ncbi.nlm.nih.gov/pubmed/12706763http://www.ncbi.nlm.nih.gov/pubmed/12706763http://www.ncbi.nlm.nih.gov/pubmed?term=Fletcher%20D%5BAuthor%5D&cauthor=true&cauthor_uid=12706763http://www.ncbi.nlm.nih.gov/pubmed?term=Chauvin%20M%5BAuthor%5D&cauthor=true&cauthor_uid=12706763http://www.ncbi.nlm.nih.gov/pubmed?term=Baer%20M%5BAuthor%5D&cauthor=true&cauthor_uid=12706763http://www.ncbi.nlm.nih.gov/pubmed?term=Dolveck%20F%5BAuthor%5D&cauthor=true&cauthor_uid=12706763http://www.ncbi.nlm.nih.gov/pubmed?term=Templier%20F%5BAuthor%5D&cauthor=true&cauthor_uid=12706763http://www.ncbi.nlm.nih.gov/pubmed/12972896


3/16

For a volume per minute > 15 l x min(-1) and < 20 l x min(-1), measured FIO2 ranges from 59 to 83vol % depending on the variations of RR and VT.

CONCLUSION:Boussignac CPAP with 100 vol % oxygen input, delivers high levels of FIO2, especially for volumeper minute values usually met in cAPE. The needed oxygen flow is lower than what is usually

required by other CPAP flow generators using the venturi effect that may be used in out-of-hospitalmedical care.

4-Boussignac CPAP in the postoperative period in morbidlyobese patients.Gaszynski T,Tokarz A,Piotrowski D,Machala W.Author information

AbstractBACKGROUND:

In the postoperative period hypoventilation and hypoxia with hypercarbia may occur in morbidlyobese patients due to the residual influence of general anesthesia drugs, postoperative atelectasisand postoperative pain. Non-Invasive Ventilation (NIV) is a method of improvement of respiratoryefficiency in patients not requiring mechanical ventilation. The aim of the study was to compare NIV(Boussignac) CPAP and traditional oxygen delivery via nasal catheter in the postoperative acutecare unit (PACU) in morbidly obese patients after open Roux-en-Y gastric bypass (RYGBP).

METHODS:19 morbidly obese patients scheduled for elective open RYGBP, were randomly divided into 2groups: CPAP (10 patients) or control (nasal catheter - 9 patients). Patients consisted of: 8 maleand 11 female, mean weight 127.76 +/- 18.5 kg, height 173.41 +/- 9.41 cm, BMI 42.43 +/- 3.3kg/m2, age 35.84 +/- 9.05 years. In the PACU, capillary blood gas measurements were taken at 3

Time Points: T1 - 30 min, T2 - 4 hours and T3 - 8 hours after admission. Sample T0 was takenbefore surgery. For management of postoperative pain, patients received morphine 2 mg/hintravenously and tramadol 100 mg.

RESULTS:Mean blood gas measurements of all postoperative time points were: pO2 81.0+/-16.0 (range 78.1-85.7) mmHg vs 65.9+/-4.9 (range 63.8-68.1) mmHg (P0.05), in the CPAP and control groupsrespectively. In every case, pulse-oxymetry oxygenation was >94%.

CONCLUSION:Boussignac CPAP improved blood oxygenation compared to passive oxygenation with a nasalcatheter but had no influence on CO2 elimination in non-CO2 retaining morbidly obese patients.

5-Continuous positive airway pressure via the Boussignacsystem immediately after extubation improves lung functionin morbidly obese patients with obstructive sleep apneaundergoing laparoscopic bariatric surgery.
http://www.ncbi.nlm.nih.gov/pubmed?term=Gaszynski%20T%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Gaszynski%20T%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Tokarz%20A%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Tokarz%20A%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Tokarz%20A%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Piotrowski%20D%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Piotrowski%20D%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Piotrowski%20D%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Machala%20W%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Machala%20W%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Machala%20W%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed/17608255http://www.ncbi.nlm.nih.gov/pubmed/17608255http://www.ncbi.nlm.nih.gov/pubmed/17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Machala%20W%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Piotrowski%20D%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Tokarz%20A%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Gaszynski%20T%5BAuthor%5D&cauthor=true&cauthor_uid=17608255


4/16

Neligan PJ,Malhotra G,Fraser M,Williams N,Greenblatt EP,Cereda M,Ochroch EA.Author information

AbstractBACKGROUND:Morbidly obese patients are at elevated risk of perioperative pulmonary complications, including

airway obstruction and atelectasis. Continuous positive airway pressure may improve postoperativelung mechanics and reduce postoperative complications in patients undergoing abdominal surgery.

METHODS:Forty morbidly obese patients with known obstructive sleep apnea undergoing laproscopic bariatricsurgery with standardized anesthesia care were randomly assigned to receive continuous positiveairway pressure via the Boussignac system immediately after extubation (Boussignac group) orsupplemental oxygen (standard care group). All subjects had continuous positive airway pressureinitiated 30 min after extubation in the postanesthesia care unit via identical noninvasive ventilators.The primary outcome was the relative reduction in forced vital capacity from baseline to 24 h afterextubation.

RESULTS:

Forty patients were enrolled into the study, 20 into each group. There were no significantdifferences in baseline characteristics between the groups. The intervention predicted lessreduction in all measured lung functions: forced expiratory volume in 1 s (coefficient 0.37, SE 0.13,P = 0.003, CI 0.13-0.62), forced vital capacity (coefficient 0.39, SE 0.14, P = 0.006, CI 0.11-0.66),and peak expiratory flow rate (coefficient 0.82, SE 0.31, P = 0.008, CI 0.21-0.1.4).

CONCLUSIONS:Administration of continuous positive airway pressure immediately after extubation maintainsspirometric lung function at 24 h after laparoscopic bariatric surgery better than continuous positiveairway pressure started in the postanesthesia care unit.

6-Effects Of Boussignac CPAP Mask VsVenturi Mask On Postoperative Gas

Exchange After Lung ResectionLuis Puente-Maestu , MD,PhD1, Ignacio Garutti , MD2, Paula

Rodriguez , MD3, Liliana Moran , MD3, JuanLaso , MD2, Raul Sevilla , MD2,

Publication Date: 2013

Read More:http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A5723
http://www.ncbi.nlm.nih.gov/pubmed?term=Neligan%20PJ%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Neligan%20PJ%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Malhotra%20G%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Malhotra%20G%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Malhotra%20G%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Fraser%20M%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Fraser%20M%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Fraser%20M%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Williams%20N%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Williams%20N%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Williams%20N%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Greenblatt%20EP%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Greenblatt%20EP%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Greenblatt%20EP%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Cereda%20M%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Cereda%20M%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Cereda%20M%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Ochroch%20EA%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Ochroch%20EA%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Ochroch%20EA%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed/19293693http://www.ncbi.nlm.nih.gov/pubmed/19293693http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A5723http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A5723http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A5723http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A5723http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A5723http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A5723http://www.ncbi.nlm.nih.gov/pubmed/19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Ochroch%20EA%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Cereda%20M%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Greenblatt%20EP%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Williams%20N%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Fraser%20M%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Malhotra%20G%5BAuthor%5D&cauthor=true&cauthor_uid=19293693http://www.ncbi.nlm.nih.gov/pubmed?term=Neligan%20PJ%5BAuthor%5D&cauthor=true&cauthor_uid=19293693


5/16

7- Role of the Boussignac Continuous Positive

Pressure Mask in

the Emergency Department

Eisenman A MDa,b, Rusetski V MDa

, Sharivker D MDa

, Avital RN MAa

a Department of Emergency Medicine, Western Galilee Hospital, Naharia, Israel b Rappaport

Faculty of Medicine, Israel Institute of TechnologyTechnion, Haifa, Israel

Abstract

Objectives: (1) To determine whether noninvasive continuous positive airway pressure (CPAP)

ventilation

with the Boussignac face mask can reverse acute respiratory failure in patients with congestive

heart failure

(CHF) or chronic obstructive pulmonary disease (COPD) in the emergency department (ED); (2) To

characterize patients who may benefit from this method.


6/16

Methods: Patients presenting to the ED in 2004 with respiratory distress, who were referred for

mechanical

ventilation, were first allocated to a treatment trial with Boussignac-CPAP. Success was defined as

an

improvement in respiratory parameters without subsequent need for endotracheal intubation.

Data were

collected on demographic and clinical features, diagnosis and respiratory parameters, door-to-

treatment

interval, and outcome.

Results: The sample included 86 patients of average age 74.3 years. The main indications for CPAP

ventilation were CHF (78%), diagnosed mainly by chest x-ray, and COPD (54.6%), diagnosed mainly

by

physical examination. The large majority of patients were conscious (90.7%) and fully cooperative

(83%).

Average time from admission to ventilation was 16+22 minutes. Respiratory parameters improved

in 80

patients (93%); the major improvement occurred within the first 30 minutes of treatment. Only 6

patients

(7%) subsequently required full ventilation. Sixty-nine patients (91%) were admitted to generalmedical

wards and 7 (9%) to the intensive care unit; the remainder were discharged home.

Conclusions: Noninvasive CPAP via the Boussignac face mask is a near-ideal means of ventilation in

the

ED, provided patients are carefully selected. It improves respiratory distress in most patients; is

associated

with very few side effects; and spares patients full mechanical ventilation.

pag web:

http://isrjem.org/Isrjem_June08.CPAP%20Eisenman_Postprod.pdf


7/16

8-The usage of the Boussignac continuous positive airway pressure system in acuterespiratory failure

Wong D. T. 1, Tam A. D. 2, Van Zundert T. C. R. V. 31Department of Anesthesia, Toronto Western Hospital, University of Toronto, ON, Canada;2College of Biological Science, University of Guelph, ON, Canada;3Department of Anesthesia, Maastricht University Medical Centre, Maastricht, The Netherlands

Traditionally, continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BiPAP)devices have been used to treat patients in acute respiratory failure. However they require an electric

power source, are relatively large in size, and may be difficult to use in prehospital settings. Therecently introduced Boussignac CPAP system is capable of delivering 10 cmH2O of CPAP, is compact,

portable and requires only an oxygen source. This paper reviews the efficacy of using Boussignac

CPAP as a treatment for acute respiratory failure in both prehospital and hospital settings. All studies

mainly focused on patients treated for cardiogenic pulmonary edema. In the prehospital setting,

Boussigac CPAP significantly improved respiratory parameters and oxygenation from baseline values.

In the emergency department setting, Boussignac CPAP was more effective than standard oxygen

delivery and just as effective as BiPAP in improving patient oxygenation and respiration. In one study,

implementing Boussignac CPAP reduced intubation rate and hospital stay. Most hospital staff found

Boussignac CPAP easy to use and complication rates were low. Boussigac CPAP is a useful device in

the treatment of patients with acute respiratory failure, especially in the prehospital setting.lingua: Inglese

pagian web:

http://www.minervamedica.it/it/riviste/minerva-

anestesiologica/articolo.php?cod=R02Y2013N05A0564

9-Practical use, effects and complicationsof prehospital treatment of acutecardiogenic pulmonary edema using theBoussignac CPAP systemEva Eiske Spijker12

*, Maarten de Bont3,Matthijs Bax4and Maro Sandel5

10- CPAP de Boussignac en procedimientos

diagnstico-teraputicos

en pacientes crticos -scielo-

.
http://www.intjem.com/content/6/1/8/#ins1http://www.intjem.com/content/6/1/8/#ins1http://www.intjem.com/content/6/1/8/#ins1http://www.intjem.com/content/6/1/8/#ins3http://www.intjem.com/content/6/1/8/#ins3http://www.intjem.com/content/6/1/8/#ins3http://www.intjem.com/content/6/1/8/#ins4http://www.intjem.com/content/6/1/8/#ins4http://www.intjem.com/content/6/1/8/#ins4http://www.intjem.com/content/6/1/8/#ins5http://www.intjem.com/content/6/1/8/#ins5http://www.intjem.com/content/6/1/8/#ins5http://www.intjem.com/content/6/1/8/#ins5http://www.intjem.com/content/6/1/8/#ins4http://www.intjem.com/content/6/1/8/#ins3http://www.intjem.com/content/6/1/8/#ins1http://www.intjem.com/content/6/1/8/#ins1


8/16

Bing:

1-La CPAP de Boussignac preserva la

funcin pulmonar tras la cirugabaritrica laparoscpica2-3 guias para el uso en urgencias y emergencias

4- protocolo de bolsillo

5-CPAP BOUSSIGNAC: PROTOCOLO DEACTUACION Y CUIDADOS DE ENFERMERIA

6-Vlvula de Boussignac y CPAP frente a diferentes situaciones detemperatura y humedad ambientalResumen

INTRODUCCIN. La vlvula de Boussigna permiteentregar un nivel de presin positiva continua enva area (CPAP) a los enfermos, con la nica necesidad de una fuente de gas de alto flujo.Estudiamos si las variaciones en la humedad y temperatura podran afectar al dispositivo de CPAP.MATERIAL Y MTODO. Estudio experimental, realizado en condiciones de laboratorio. Medimos laCPAP conseguida mediante una vlvula de Boussignac de Vygon ante distintas condiciones dehumedad y temperatura ambiental. Se utilizaron, adems de la citada vlvula, una fuente de O2medicinal con un caudalmetro, un serpentn de cobre para calentar/enfriar el gas, un humidificadorRespiflo de Kendall, y una cubeta de aislamiento trmico. Las mediciones de CPAP se hicieron conun manmetro digital, y las de temperatura y humedad con un termo-higrmetro (previamentecalibrados). Tras realizar varias mediciones para un mismo flujo, ante distintas condiciones de

humedad y temperatura, se compararon los resultados obtenidos mediante la prueba de la "t" deStudent (comparaciones dos a dos) y ANOVA. Se demand un intervalo de confianza mnimo de 95%.RESULTADOS. Para los diferentes flujos analizados (15, 20 y 25 litros/minuto) se comprueba cmoante distintas condiciones de temperatura (en rangos de 4-6 C, 24-26 C y 40-42 C) y humedad (2%,15-20%, 35-40% y 80-85%) se obtienen diferencias estadsticamente significativas en los niveles deCPAP entregados. CONCLUSIN. La temperatura y la humedad a la que se utilicen el oxgeno y eldispositivo de CPAP de Boussignac influyen en los niveles de presin obtenidos, pudiendo llegar adiferencias de presin cercanas al 20% en algunas circunstancias, para un mismo flujo.

7-CPAPDE BOUSSIGNACEN URGENCIAS.EvaListaArias, Javier Jacob Rodrguez, Xavier Palom Rico, Gilberto Alonso Fernndez

RESUMEN

Sr. Director hemos ledo con inters la revisin de JM. Carratala y J. Masip, Laventilacin no invasivaen la insuficiencia cardiaca aguda: uso de CPAPen los serviciosde

urgencias1, sabiendo que es una tcnica poco utilizada en urgencias

2, en


9/16

nuestro hospitalpusimos en marcha un proyecto para usarla ms, concretamente

la CPAPde Boussignac, al ser un sistema fcil, verstil ybaratode aplicacin de presin

positiva en el edema agudo de pulmn hipoxmico.Nuestraexperiencia es de 10 casos, 8

mujeres y 2 hombres, con una edad mediade 79.8 aos, la mejora de la disnea fue del100%, trabajo respiratorio (escala de Patrick) del 100%, remisin total del 70% y

saturacin > 95% en todos loscasos. Ningn caso preciso de IOT, la mortalidad fue nula, laduracin de la CPAP fue de 3.63 horas, no hemos tenido ningn caso en que hayamostenido que prolongarla, pues la aplicacin del restode medidas teraputicas han sido

eficaces3. Hemos acortado la duracin en 2 casos por claustrofobia, siendo inferior a 30

minutos. Deducimos que el sistema Boussignac es un buen sistema de presin positiva,pero no nos permiten una precisin de la aportacin de la presin, por lo tanto, subir o bajar

de 2 en 2 cm de H2O no es muy aplicable. Los valoresde presin aportados oscilan entre 7

y 10, guiados mayoritariamente por la saturacin arterial de oxgeno (variable inmediata)

ms que por el trabajo respiratorio (variable ms tarda). Tampoco permite la deteccin,

medida o correccin de la fuga, nicamente el manmetro nos indica la demanda de presininspiratoria del paciente y nosotros debemos interpretar si es por fuga o por fatiga

inspiratoria, por lo que aceptamos una variabilidad de 2 cm de H2O; de acuerdo con los

autores, los sistemas de CPAPno pueden considerarse propiamente sistemas de ventilacin,por lo que la fuga es un elementoperdidoen estas situaciones.

En el manejo del edemapulmonarque cursa con hipercapnia, estamos de acuerdo en

emplear el doble nivel de presin, siendo fundamental el control de la fuga4. Pensamos que

aportar una FIO2 mxima, del 100% segn los autores, en el sndromehipercpnico no es

apropiado, y menos an cuando podemos optimizar la saturacin de oxgeno con la presin

espiratoria, es ms, este parmetro debera ser el ltimo en manipularse en situaciones dehipercapnia.

1. Carratala JM, Masip J. Ventilacin no invasiva en la insuficiencia cardiacaaguda: uso

de CPAPen los servicios de urgencias. Emergencias 2010; 22: 49-55.

2. LLorens P et al. Perfil clnicode los pacientes con Insuficiencia Cardiaca en losServicios de Urgencias: Datos preliminares del estudio EAHFE (Epidemiology Acute Heart

FailureEmergency). Emergencias 2008;20:154-63.

3. Carballo Cardona C, MorenoZabaleta R, Moreno Planelles MD. Ventilacin noinvasiva en los servicios de urgencias. Revista Iberoamericana de Ventilacin Mecnica no

Invasiva 2009; 13:32-39.

4. Ayuso Baptista F, Jimnez Moral G, Fonseca del Pozo. Manejo de la insuficiencia

respiratoria aguda con ventilacin mecnica no invasiva en urgencias y emergencias.Emergencias 2009; 21:189-20

8-Ttulo:

CPAP de Boussignac en procedimientos diagnstico-teraputicos en pacientes crticos

Claves:CPAP BoussignacFibrobroncoscopiaEndoscopiaHemorragia digestivaInsuficiencia respiratoria agudaEdema agudo de pulmn


10/16

La vlvula de Boussignac se ha convertido en un elemento a tener en cuenta en el manejo el edema agudode pulmn. Gracias a su capacidad para generar presin positiva continua en la va area (CPAP) y susimplicidad, su utilizacin se est extendiendo en los servicios de emergencias y de urgencias y las plantasde hospitalizacin. Consiste en un pequeo tubo que se coloca sobre el puerto espiratorio de la mascarilla.El flujo (oxgeno/aire) se acelera al pasar a travs de cuatro microcanales que existen en la pared de lavlvula, y por el principio de la energa en movimiento, consiguen presurizar el rbol bronquial. Su sistemade funcionamiento, no hermtico, permite el paso de una sonda a travs de ella para asistir al paciente(beber, alimentarse, aspirar, etc.). Ello la capacita para ampliar su utilizacin en pacientes que, estando ensituacin lmite, necesitan pruebas diagnsticas que pudieran empeorar la situacin respiratoria, como losprocedimientos endoscpicos. Presentamos a 3 pacientes crticos a los que se administr CPAP con unavlvula de Boussignac acoplada a una mascarilla orofacial durante la realizacin de dos fibrobroncoscopiasy una endoscopia digestiva alta. Los 3 casos culminaron con xito y no se necesit la intubacinorotraqueal.

9-Utilizacin de la CPAP de Boussignac en la Sedacin enendoscopia Autores:Francisca Gmez Garca,Luis Margaix Margaix,Rosa Zaragoza Gradoli,Amparo Rubio Valverde Localizacin:Enfermera integral: Revista cientfica del Colegio Oficial de A.T.S de Valencia,ISSN 0214-

0128,N. 90, 2010, pgs. 33-36

o Texto Completo Ejemplar Resumeno El desarrollo de la endoscopiaen los ltimos aos ha trado como consecuencia una gran variedad de

procedimientos diagnsticos y teraputicos, que pueden resultar incmodos y dolorosos para el paciente .El

papel del anestesilogo en estas situaciones es muy importante para garantizar la confortabilidad y la

seguridad del paciente.La CPRE (colangiopancreatografi a retrograda endoscopia) es una tcnica muy molesta ya que hay que

invertirnormalmente mucho tiempo en ella, y adems es muy importante mantener al paciente inmvil. Por

ste motivo, la realizamos siempre con sedacin profunda, ya que se reconoce que el disconfort, la

inmovilidad y la duracin de la CPRE disminuyen la tolerancia y condicionan el xito del procedimiento. Es

sobre todo en stos casos cuando comenzamos a utilizar la CPAP, ya que observamos junto con los

anestesistas que mejoraba la oxigenacin del paciente.

La CPAPde Boussignac es un dispositivo no mecnico de Ventilacin no Invasiva, cilndrico, hueco y ligero

(slo 6.5 gr.) de 5,6 cm. de largo por 2,2 cm. de dimetro que se conecta a una mascarilla facial por su

extremo proximal (racor macho), quedando el extremo distal (dentado) abierto al exterior.

La CPAP de Boussignac aplica una presin positiva constanteen la va area del paciente mientras ste

respira espontneamente; dicha presin se mantienen en un valor superioral atmosfrico en todo el ciclo

respiratorio.

La Presin Positiva Continuaen la Va Area-Continuos PositiveAirwayPresure- o CPAP es un modo

ventilatorio que pretende la optimizacin de la ventilacin del paciente en situacin de hipoxemia y es

utilizable sin invadir su va area.

copyscape: se dedica a encontrar sitios que han citado contenido sin autorizacion.
http://dialnet.unirioja.es/servlet/autor?codigo=1823117http://dialnet.unirioja.es/servlet/autor?codigo=1823117http://dialnet.unirioja.es/servlet/autor?codigo=1823117http://dialnet.unirioja.es/servlet/autor?codigo=1823065http://dialnet.unirioja.es/servlet/autor?codigo=1823065http://dialnet.unirioja.es/servlet/autor?codigo=1823065http://dialnet.unirioja.es/servlet/autor?codigo=2575279http://dialnet.unirioja.es/servlet/autor?codigo=2575279http://dialnet.unirioja.es/servlet/autor?codigo=2575279http://dialnet.unirioja.es/servlet/autor?codigo=1823118http://dialnet.unirioja.es/servlet/autor?codigo=1823118http://dialnet.unirioja.es/servlet/autor?codigo=1823118http://dialnet.unirioja.es/servlet/revista?codigo=3757http://dialnet.unirioja.es/servlet/revista?codigo=3757http://dialnet.unirioja.es/servlet/revista?codigo=3757http://dialnet.unirioja.es/servlet/ejemplar?codigo=249633http://dialnet.unirioja.es/servlet/ejemplar?codigo=249633http://dialnet.unirioja.es/servlet/ejemplar?codigo=249633http://dialnet.unirioja.es/servlet/ejemplar?codigo=249633&info=open_link_ejemplarhttp://dialnet.unirioja.es/servlet/ejemplar?codigo=249633&info=open_link_ejemplarhttp://dialnet.unirioja.es/servlet/ejemplar?codigo=249633&info=open_link_ejemplarhttp://dialnet.unirioja.es/servlet/ejemplar?codigo=249633http://dialnet.unirioja.es/servlet/revista?codigo=3757http://dialnet.unirioja.es/servlet/autor?codigo=1823118http://dialnet.unirioja.es/servlet/autor?codigo=2575279http://dialnet.unirioja.es/servlet/autor?codigo=1823065http://dialnet.unirioja.es/servlet/autor?codigo=1823117


11/16

cuil:

1-CPAP BOUSSIGNAC: PROTOCOLO DE ACTUACIONY CUIDADOS DE ENFERMERIA

2- GUA PARA EL USO DEL

CPAP BOUSSIGNAC

SERVICIO DE URGENCIAS

HOSPITAL SAN PEDRO - LOGROO

3-Boussignac CPAP in acute respiratory failureFederico Lari, Francesco Savelli, Fabrizio Giostra, Gianpaolo Bragagni, Nicola Di Battista

Abstract

Introduction: The application of continuous positive airway pressure(CPAP) is one of the mostimportant therapeutic interventions used in patients with acute respiratory failure (ARF) secondaryto acute cardiogenic pulmonary edema (ACPE). Thanks to its positive effects on bothhemodynamics and ventilation, CPAP improves clinical and blood-gas parameters. Compared withstandard oxygen therapy, use of CPAP is associated with decreased mortality and reduced needfor intubation in these patients.

Aimof the study: This review examines the principles of CPAP, techniques and equipment used to

deliver it, and clinical applications. Special emphasis is placed on CPAP delivered with theBoussignac device.Discussion and conclusions: In emergency departments, this simple, lightweight, disposable devicehas proved to be well tolerated and similar to Venturi-like flow generators in terms of effectiveness.These findings suggest that Boussignac CPAP might be useful for managing ARF in non-criticalcareareas where other more complicated CPAP equipment(Venturi-like flow generators andventilators) are not available (for example, in general medical wards).

4-Boussignac CPAP in the postoperative period in morbidly

obese patients.Gaszynski T,Tokarz A,Piotrowski D,Machala W.Author information

AbstractBACKGROUND:In the postoperative period hypoventilation and hypoxia with hypercarbia may occur in morbidlyobese patients due to the residual influence of general anesthesia drugs, postoperative atelectasisand postoperative pain. Non-Invasive Ventilation (NIV) is a method of improvement of respiratory
http://www.ncbi.nlm.nih.gov/pubmed?term=Gaszynski%20T%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Gaszynski%20T%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Tokarz%20A%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Tokarz%20A%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Tokarz%20A%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Piotrowski%20D%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Piotrowski%20D%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Piotrowski%20D%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Machala%20W%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Machala%20W%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Machala%20W%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed/17608255http://www.ncbi.nlm.nih.gov/pubmed/17608255http://www.ncbi.nlm.nih.gov/pubmed/17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Machala%20W%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Piotrowski%20D%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Tokarz%20A%5BAuthor%5D&cauthor=true&cauthor_uid=17608255http://www.ncbi.nlm.nih.gov/pubmed?term=Gaszynski%20T%5BAuthor%5D&cauthor=true&cauthor_uid=17608255


12/16

efficiency in patients not requiring mechanical ventilation. The aim of the study was to compare NIV(Boussignac) CPAP and traditional oxygen delivery via nasal catheter in the postoperative acutecare unit (PACU) in morbidly obese patients after open Roux-en-Y gastric bypass (RYGBP).

5-Vlvula de Boussignac y CPAPfrente a diferentes situaciones detemperatura y humedad ambiental

6-[Laboratory testing measurement of FIO2 delivered byBoussignac CPAP system with an input of 100% oxygen].

7-Use of the Boussignac CPAP System Immediately FollowingExtubation to Improve Lung Function in Adults With Moderate toSevere Obstructive Sleep Apnea

pagina web:

http://clinicaltrials.gov/show/NCT01877928

8-Vlvula de Boussignac y CPAP frente a diferentes situaciones

de temperatura y humedad ambiental (dialnet)

9-Article

[Laboratory testing measurement of FIO2 delivered by Boussignac

CPAP system with an input of 100% oxygen].

F Templier,F Dolveck,M Baer,M Chauvin,D Fletcher

Samu 92-Smur Garches, hpital Raymond-Poincar, 104, boulevard Raymond-Poincar, 92380, Garches,

France.
http://www.researchgate.net/researcher/5474501_F_Templier/http://www.researchgate.net/researcher/38825612_F_Dolveck/http://www.researchgate.net/researcher/65124962_M_Baer/http://www.researchgate.net/researcher/65123509_M_Chauvin/http://www.researchgate.net/researcher/61452640_D_Fletcher/http://www.researchgate.net/researcher/61452640_D_Fletcher/http://www.researchgate.net/researcher/65123509_M_Chauvin/http://www.researchgate.net/researcher/65124962_M_Baer/http://www.researchgate.net/researcher/38825612_F_Dolveck/http://www.researchgate.net/researcher/5474501_F_Templier/


13/16

Annales Franaises d Anesthsie et de Ranimation (Impact Factor: 0.84). 02/2003; 22(2):103-7.

Source:PubMed

ABSTRACTCPAP(Continuous Positive Airway Pressure) is one of the treatments of the cardiogenic acute

pulmonary edema (cAPE). Among the out-of-hospital used devices, Boussignac CPAP (Vygon) shows a good

technical usability, but no analysis of delivered FIO2 is available.

To measure the FIO2 delivered to patient, using Boussignac CPAP with an input of 100 vol % oxygen. Type of

study. - Measurementin a laboratory testing.

Measurement of delivered FIO2 in a three parameters environment: expiratory positiveairwaypressure

(EPAP), respiratory rate(RR) and required oxygen flow(ROF). Laboratory test: 100 vol % oxygen input, with a

ball-type flow regulator for oxygen 0-30 l x min(-1) (Mediline), Boussignac CPAP valve with manometer

(Vygon), Michigan test lung, ventilator Csar (Taema), oxygen analysis (Servomex) with paramagnetic sensor,

with a response time < 10 s, pneumotachographe (Fleisch v 2).

Under 10 cmH2O EPAP, the required oxygen flow is < or = 30 l x min(-1). Measured FIO2 ranges from 70 to

100 vol %, for a volume per minute < or = 15 l x min(-1) except for a EPAP at 2.5 cmH2O with a rate = 10 c

min(-1) and a tidal volume(VT) at 1500 ml where the measured FIO2 is 60 vol %. For a volume per minute >

15 l x min(-1) and < 20 l x min(-1), measured FIO2 ranges from 59 to 83 vol % depending on the variations of

RR and VT.Boussignac CPAP with 100 vol % oxygen input, delivershigh levelsof FIO2, especially for volume per minute

values usually met in cAPE. The needed oxygen flow is lower than what is usually required by other CPAP flow

generators using the venturi effect that may be used in out-of-hospital medical care.

10- Pneumatic Performance of the Boussignac

CPAP System in Healthy Humans

Maria Sehlin RPT MSc, Siv Sandkvist To rnell MD, Fredrik O hberg PhD,

Go ran Johansson MSc, and Ola Winso MD PhD

11- CPAP-valve (Boussignac) during Resuscitation

Track this topic |Email this topic |Print this topic

svanhooreweghe Posted:Jul 6 2005, 09:48 AM

Group:

Full Member

Posts: 5Member No.: 1411Joined: 1-October 02

As I saw a representative yesterday who very nicely tried te convinceme of the benefits of the boussignac CPAPendotracheal tube(Vygon)in reanimation, I would like to know if anybody has experience withthis device.As perfusion pressure only builds up very slowely the trend is to

augment the amount of cardiac compressions before interruption byinsufflation. We now are on 15:2.With this Boussignac-tubethe lungs are slightly insufflatedspontaneously after every compression, due to the small amount ofPEEP, hence cardiac compressions would not anymore have to beinterrupted by insufflation.Is this gods way to show how much helikes us, or is this justanother hype?
http://www.researchgate.net/journal/0750-7658_Annales_Francaises_d_Anesthesie_et_de_Reanimationhttp://www.ncbi.nlm.nih.gov/pubmed/12706763https://www.erc.edu/forum/index.php?s=0&act=Track&f=4&t=342https://www.erc.edu/forum/index.php?s=0&act=Forward&f=4&t=342https://www.erc.edu/forum/index.php?s=0&act=Print&client=printer&f=4&t=342https://www.erc.edu/forum/index.php?s=0&act=Print&client=printer&f=4&t=342https://www.erc.edu/forum/index.php?s=0&showuser=1411https://www.erc.edu/forum/index.php?s=0&showuser=1411https://www.erc.edu/forum/index.php?s=0&act=Post&CODE=06&f=4&t=342&p=905https://www.erc.edu/forum/index.php?s=0&act=Post&CODE=06&f=4&t=342&p=905https://www.erc.edu/forum/index.php?s=0&act=Post&CODE=06&f=4&t=342&p=905https://www.erc.edu/forum/index.php?s=0&showuser=1411https://www.erc.edu/forum/index.php?s=0&act=Print&client=printer&f=4&t=342https://www.erc.edu/forum/index.php?s=0&act=Forward&f=4&t=342https://www.erc.edu/forum/index.php?s=0&act=Track&f=4&t=342http://www.ncbi.nlm.nih.gov/pubmed/12706763http://www.researchgate.net/journal/0750-7658_Annales_Francaises_d_Anesthesie_et_de_Reanimation


14/16

12- The Practitioner

Le practicien

The occasional acute application of

continuous positive airway pressure

13-Active Humidification WithBoussignac CPAP: In Vitro Study of aNew Method

14-Use of the Boussignac CPAP System Immediately FollowingExtubation to Improve Lung Function in Adults With Moderate toSevere Obstructive Sleep Apnea

15-BOUSSIGNAC PRESENTA LAS NOVEDADES EN REANIMACIN CARDIOVASCULAR

El General de Alicante actualiza la formacin enventilacin no invasiva en Urgencias

Redaccin Alicante

El Serviciode Emergencias Sanitarias (SES) de Alicante ha organizado, con la colaboracin

de la Sociedad Cientfica de Urgencias y Emergencias Autonmica y Nacional, la Jornada

de Actualizacin en Ventilacin No Invasiva (VMNI) en Urgencias-Emergencias", as como

un encuentro con el doctor Georges Boussignac.


15/16

Este especialista, que se encuentra entre los

ponentes expertos tanto a nivel autonmico como nacional, es pionero en VMNI a nivel

mundial y ha presentado las novedades actuales en reanimacin cardiopulmonar.

Estajornadacuentacon un foro de ms de 300 personas inscritas, entre los quese

encuentran directivos de los servicios de Emergencias de otras comunidades autnomas,

as como diversos jefes de Servicio de Urgencias Hospitalarios.

MercedesCarrasco, directora del SES-Alicante, ha destacado el repaso que se hace de las

indicaciones y beneficios de la VMNI y de los registros que ya se han realizado a nivel

nacional. Tambin se han presentado las novedades en reanimacin cardiopulmonar

Sistema CpapBoussignac

La ventilacion no invasiva(VMNI) y su aplicacin con la CPAP de Boussignac representan

"un espectacular avance en el tratamiento inicialen los pacientes aquejados de fracaso

respiratorio agudo", segn explican los especialistas, e incide directamente en grandes

beneficios para los enfermos, ya que disminuye la morbi-mortalidad al reducir la

necesidad de intubacin orotraqueal y conexin a ventilacin mecnica. Adems, acorta la

estancia en los Servicios de Medicina Intensiva. Su aplicacin precoz en el mbito

prehospitalario est garantizando estos resultados.

web: http://cardiologia.publicacionmedica.com/spip.php?article412


16/16

15-Effects Of Boussignac CPAP Mask VsVenturi Mask On Postoperative Gas

Exchange After Lung ResectionLuis Puente-Maestu , MD,PhD1, Ignacio Garutti , MD2, Paula

Rodriguez , MD3, Liliana Moran , MD3, JuanLaso , MD2, Raul Sevilla , MD2,

Publication Date: 2013

Read More:http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A5723

16-Manejo de la insuficiencia respiratoria aguda

con ventilacin mecnica no invasiva en urgencias

y emergencias

FERNANDO AYUSO BAPTISTA1

, GABRIEL JIMNEZ MORAL2

, FRANCISCO JAVIER FONSECA DEL POZO3

exalead: me aparece 0 resultados

duckduckgo: seguir....

1-https://duckduckgo.com/?q=cpap+boussignac
http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A5723http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A5723http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A5723http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A5723http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A5723http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A5723

2da busqueda

Documents